Literature DB >> 30106803

Acute Management of Optic Neuritis: An Evolving Paradigm.

Lindsay Horton1, Jeffrey L Bennett.   

Abstract

The current management of acute optic neuritis (ON) is focused on expediting visual recovery through the use of high-dose intravenous corticosteroids. The recent identification of specific autoantibodies associated with central nervous system inflammatory disorders has provided novel insights into immune targets and mechanisms that impact the prognosis, treatment, and recurrence of ON. Therefore, neurologists and ophthalmologists need to be aware of clinical, laboratory, and imaging findings that may provide important clues to the etiology of ON and the potential need for aggressive management. Moving forward, rapid and accurate diagnosis of inflammatory ON will likely be critical for implementing clinical care that optimizes short-term and long-term therapeutic outcomes.

Entities:  

Year:  2018        PMID: 30106803      PMCID: PMC6370553          DOI: 10.1097/WNO.0000000000000700

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  101 in total

1.  Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.

Authors:  L M Metz; D Sabuda; R J Hilsden; R Enns; J B Meddings
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

2.  Relapsing optic neuritis: a multicentre study of 62 patients.

Authors:  Aurélien Benoilid; Caroline Tilikete; Nicolas Collongues; Carl Arndt; Alain Vighetto; Catherine Vignal; Jérôme de Seze
Journal:  Mult Scler       Date:  2013-10-31       Impact factor: 6.312

3.  Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Authors:  Bernardo Sanchez-Dalmau; Elena H Martinez-Lapiscina; Ruben Torres-Torres; Santiago Ortiz-Perez; Irati Zubizarreta; Irene V Pulido-Valdeolivas; Salut Alba-Arbalat; Ana Guerrero-Zamora; David Calbet; Pablo Villoslada
Journal:  Mult Scler       Date:  2017-07-03       Impact factor: 6.312

4.  Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.

Authors:  Maureen A Mealy; Anna Whetstone; Gunes Orman; Izlem Izbudak; Peter A Calabresi; Michael Levy
Journal:  J Neurol Sci       Date:  2015-05-17       Impact factor: 3.181

5.  Different etiologies and prognoses of optic neuritis in demyelinating diseases.

Authors:  Tetsuya Akaishi; Ichiro Nakashima; Takayuki Takeshita; Kimihiko Kaneko; Shunji Mugikura; Douglas Kazutoshi Sato; Toshiyuki Takahashi; Toru Nakazawa; Masashi Aoki; Kazuo Fujihara
Journal:  J Neuroimmunol       Date:  2016-09-14       Impact factor: 3.478

6.  Neuro-ophthalmic sarcoidosis: the University of Iowa experience.

Authors:  Jacob J Koczman; Jacinthe Rouleau; Morgan Gaunt; Randy H Kardon; Michael Wall; Andrew G Lee
Journal:  Semin Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.975

Review 7.  The investigation of acute optic neuritis: a review and proposed protocol.

Authors:  Axel Petzold; Mike P Wattjes; Fiona Costello; Jose Flores-Rivera; Clare L Fraser; Kazuo Fujihara; Jacqueline Leavitt; Romain Marignier; Friedemann Paul; Sven Schippling; Christian Sindic; Pablo Villoslada; Brian Weinshenker; Gordon T Plant
Journal:  Nat Rev Neurol       Date:  2014-07-08       Impact factor: 42.937

8.  Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis.

Authors:  R T Naismith; N T Tutlam; J Xu; E C Klawiter; J Shepherd; K Trinkaus; S-K Song; A H Cross
Journal:  Neurology       Date:  2009-03-24       Impact factor: 9.910

9.  Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.

Authors:  Sung-Min Kim; Mark R Woodhall; Ji-Sun Kim; Seong-Joon Kim; Kyung Seok Park; Angela Vincent; Kwang-Woo Lee; Patrick Waters
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-10-15

10.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.

Authors:  Florence Pache; Hanna Zimmermann; Janine Mikolajczak; Sophie Schumacher; Anna Lacheta; Frederike C Oertel; Judith Bellmann-Strobl; Sven Jarius; Brigitte Wildemann; Markus Reindl; Amy Waldman; Kerstin Soelberg; Nasrin Asgari; Marius Ringelstein; Orhan Aktas; Nikolai Gross; Mathias Buttmann; Thomas Ach; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt
Journal:  J Neuroinflammation       Date:  2016-11-01       Impact factor: 8.322

View more
  7 in total

Review 1.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

2.  Contemporary management challenges in seropositive NMOSD.

Authors:  Fiona Costello; Jodie M Burton
Journal:  J Neurol       Date:  2022-07-11       Impact factor: 6.682

3.  Predictors of Glucocorticoid Use for Acute Optic Neuritis in the United States, 2005-2019.

Authors:  Lindsey B De Lott; Chun Chieh Lin; James F Burke; Beth Wallace; Daniel Saukkonen; Akbar K Waljee; Kevin A Kerber
Journal:  Ophthalmic Epidemiol       Date:  2022-02-16

Review 4.  Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.

Authors:  George Saitakis; Bart K Chwalisz
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 5.  The changing landscape of optic neuritis: a narrative review.

Authors:  Lindsey B De Lott; Jeffrey L Bennett; Fiona Costello
Journal:  J Neurol       Date:  2021-01-03       Impact factor: 4.849

6.  Steroid-Resistant Double-Seronegative Optic Neuritis Responds Favorably to Plasma Exchange.

Authors:  Matthew C Mason; Dario A Marotta; Hassan Kesserwani
Journal:  Cureus       Date:  2021-05-26

7.  Isolated Double-Positive Optic Neuritis: A Case of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody Seropositivity.

Authors:  Matthew C Mason; Dario A Marotta; Hassan Kesserwani
Journal:  Cureus       Date:  2021-06-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.